董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erica J. Rogers | 女 | President, Chief Executive Officer and Director | 56 | 62.40万美元 | 未持股 | 2020-02-28 |
| Ruoxi Chen | 男 | Director | 36 | 未披露 | 未持股 | 2020-02-28 |
| Tony M. Chou | 男 | Director | 59 | 未披露 | 未持股 | 2020-02-28 |
| Robert E. Mittendorff | -- | Director | 43 | 未披露 | 未持股 | 2020-02-28 |
| Amr Kronfol | 男 | Director | 39 | 未披露 | 未持股 | 2020-02-28 |
| Elizabeth H. Weatherman | 女 | Director | 60 | 未披露 | 未持股 | 2020-02-28 |
| Donald J. Zurbay | 男 | Director | 52 | 34.82万美元 | 未持股 | 2020-02-28 |
| Jack W. Lasersohn | 男 | Director | 66 | 未披露 | 未持股 | 2020-02-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erica J. Rogers | 女 | President, Chief Executive Officer and Director | 56 | 62.40万美元 | 未持股 | 2020-02-28 |
| Lucas W. Buchanan | 男 | Chief Financial Officer | 42 | 56.00万美元 | 未持股 | 2020-02-28 |
| Andrew S. Davis | 男 | Executive Vice President of Global Sales and Marketing | 51 | 62.61万美元 | 未持股 | 2020-02-28 |
| Richard M. Ruedy | 男 | Executive Vice President of Regulatory Affairs, Clinical Affairs and Quality Assurance | 53 | 未披露 | 未持股 | 2020-02-28 |
董事简历
中英对照 | 中文 | 英文- Erica J. Rogers
-
EricaJ.Rogers自2020年9月以来一直担任我们的董事会成员。Rogers女士自2012年10月起担任Silk Road Medical Inc.（一家医疗设备制造商）的总裁兼首席执行官和董事会成员。Rogers之前从2010年6月到2012年10月担任Medicines360（一家非盈利制药公司，为女性开发药物和设备）首席运营官。Rogers女士于2008年12月至2010年3月担任量子点技术公司NanoSys，Inc.的执行Vice President。在此之前，Rogers女士创立并担任Allux Medical（一家医疗设备公司）的首席执行官，并共同创立VisioGen（一家眼科医疗设备公司，于2009年被Abbott Medical Optics收购）。她此前曾任职Target Therapeutics Inc.（医疗设备制造商）的神经血管营销，以及Boston Scientific公司（医疗设备制造商）的外周血管销售和销售培训。Rogers女士目前在Sight Sciences，Inc.（一家医疗设备公司）的董事会任职。Rogers女士在圣地亚哥州立大学（San Diego State University）获得动物学学士学位。
Erica J. Rogers has served as a member of our board of directors since September 2020. Ms. Rogers has served as President and Chief Executive Officer and a member of the board of directors of Silk Road Medical Inc., a medical equipment manufacturer, since October 2012. Ms. Rogers previously served as Chief Operating Officer of Medicines360 a non-profit pharmaceutical company developing drugs and devices for women from June 2010 to October 2012. Ms. Rogers was an Executive Vice President at Nanosys, Inc., a quantum dot technology company, from December 2008 to March 2010. Prior to that, Ms. Rogers founded and was Chief Executive Officer of Allux Medical, a medical device company, and co-founded Visiogen, an ophthalmic medical device company which was acquired by Abbott Medical Optics in 2009. She worked previously in neurovascular marketing at Target Therapeutics Inc., a medical equipment manufacturer, and peripheral vascular sales and sales training at Boston Scientific, a medical device manufacturer. Ms. Rogers currently serves on the board of directors of Sight Sciences, Inc., a medical device company. Ms. Rogers received a B.S. in zoology from San Diego State University. - EricaJ.Rogers自2020年9月以来一直担任我们的董事会成员。Rogers女士自2012年10月起担任Silk Road Medical Inc.（一家医疗设备制造商）的总裁兼首席执行官和董事会成员。Rogers之前从2010年6月到2012年10月担任Medicines360（一家非盈利制药公司，为女性开发药物和设备）首席运营官。Rogers女士于2008年12月至2010年3月担任量子点技术公司NanoSys，Inc.的执行Vice President。在此之前，Rogers女士创立并担任Allux Medical（一家医疗设备公司）的首席执行官，并共同创立VisioGen（一家眼科医疗设备公司，于2009年被Abbott Medical Optics收购）。她此前曾任职Target Therapeutics Inc.（医疗设备制造商）的神经血管营销，以及Boston Scientific公司（医疗设备制造商）的外周血管销售和销售培训。Rogers女士目前在Sight Sciences，Inc.（一家医疗设备公司）的董事会任职。Rogers女士在圣地亚哥州立大学（San Diego State University）获得动物学学士学位。
- Erica J. Rogers has served as a member of our board of directors since September 2020. Ms. Rogers has served as President and Chief Executive Officer and a member of the board of directors of Silk Road Medical Inc., a medical equipment manufacturer, since October 2012. Ms. Rogers previously served as Chief Operating Officer of Medicines360 a non-profit pharmaceutical company developing drugs and devices for women from June 2010 to October 2012. Ms. Rogers was an Executive Vice President at Nanosys, Inc., a quantum dot technology company, from December 2008 to March 2010. Prior to that, Ms. Rogers founded and was Chief Executive Officer of Allux Medical, a medical device company, and co-founded Visiogen, an ophthalmic medical device company which was acquired by Abbott Medical Optics in 2009. She worked previously in neurovascular marketing at Target Therapeutics Inc., a medical equipment manufacturer, and peripheral vascular sales and sales training at Boston Scientific, a medical device manufacturer. Ms. Rogers currently serves on the board of directors of Sight Sciences, Inc., a medical device company. Ms. Rogers received a B.S. in zoology from San Diego State University.
- Ruoxi Chen
-
Ruoxi Chen自2020年11月以来一直担任我们的董事会成员。陈先生是华平投资（Warburg Pincus）的负责人，专注于梦百合领域的投资，并于2011年加入该公司。在加入Warburg Pincus之前，陈先生在美国收购基金凯雷集团（Carlyle Group）工作，并在花旗集团（Citigroup）从事投资银行业务。他目前是Silk RoadMedical，Inc.和几家私营公司的董事会成员。他在杜克大学（Duke University）获得经济学和计算机科学学士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Ruoxi Chen has served as a member of our board of directors since November 2020. Mr. Chen is a principal at Warburg Pincus, focusing on investments in the healthcare sector, and joined the firm in 2011. Prior to joining Warburg Pincus, Mr. Chen worked at the Carlyle Group in the U.S. Buyout Fund and in investment banking at Citigroup. He is currently a board member of Silk Road Medical, Inc. and several private companies. He received a B.S. magna cum laude in economics and computer science from Duke University and an M.B.A. from Harvard Business School. - Ruoxi Chen自2020年11月以来一直担任我们的董事会成员。陈先生是华平投资（Warburg Pincus）的负责人，专注于梦百合领域的投资，并于2011年加入该公司。在加入Warburg Pincus之前，陈先生在美国收购基金凯雷集团（Carlyle Group）工作，并在花旗集团（Citigroup）从事投资银行业务。他目前是Silk RoadMedical，Inc.和几家私营公司的董事会成员。他在杜克大学（Duke University）获得经济学和计算机科学学士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Ruoxi Chen has served as a member of our board of directors since November 2020. Mr. Chen is a principal at Warburg Pincus, focusing on investments in the healthcare sector, and joined the firm in 2011. Prior to joining Warburg Pincus, Mr. Chen worked at the Carlyle Group in the U.S. Buyout Fund and in investment banking at Citigroup. He is currently a board member of Silk Road Medical, Inc. and several private companies. He received a B.S. magna cum laude in economics and computer science from Duke University and an M.B.A. from Harvard Business School.
- Tony M. Chou
-
TonyM.Chou自2007年3月以来一直担任我们的董事会成员。Chou博士从2006年8月开始一直担任垂直集团（Vertical Group）的普通合伙人，这是一家专注于梦百合的风险投资公司。加入The Vertical Group后，Chou博士于2007年联合创立了我司，并担任首席执行官直到2010年11月。在此之前，周博士曾在雅培公司的雅培血管部门担任一般管理和业务开发职责，最后担任部门Vice President和血管闭合总经理，管理Perclose和Starclose产品的FDA批准和全球发布。Chou博士之前是加州大学旧金山分校（University of California，San Francisco）成人心脏导管实验室的主任，在那里他目前是医学副教授。Chou博士在卡内基梅隆大学（Carnegie Mellon University）获得物理与电气工程学士学位，并在凯斯西储大学（Case Western Reserve University）获得医学博士学位。
Tony M. Chou has served as a member of our board of directors since March 2007. Dr. Chou has been a general partner at The Vertical Group, a healthcare-focused venture capital firm, since August 2006. After joining The Vertical Group, Dr. Chou co-founded our company in 2007 and served as Chief Executive Officer until November 2010. Prior to that, Dr. Chou had general management and business development responsibilities in the Abbott Vascular Division of Abbott Laboratories and last served as Division Vice President and General Manager of vascular closure, managing the FDA approval and global launch of the Perclose and Starclose products. Dr. Chou was previously the Director of the Adult Cardiac Catheterization Laboratory at the University of California, San Francisco, where he is currently Associate Professor of Medicine. Dr. Chou received a B.S. in physics and electrical engineering from Carnegie Mellon University and an M.D. from Case Western Reserve University. - TonyM.Chou自2007年3月以来一直担任我们的董事会成员。Chou博士从2006年8月开始一直担任垂直集团（Vertical Group）的普通合伙人，这是一家专注于梦百合的风险投资公司。加入The Vertical Group后，Chou博士于2007年联合创立了我司，并担任首席执行官直到2010年11月。在此之前，周博士曾在雅培公司的雅培血管部门担任一般管理和业务开发职责，最后担任部门Vice President和血管闭合总经理，管理Perclose和Starclose产品的FDA批准和全球发布。Chou博士之前是加州大学旧金山分校（University of California，San Francisco）成人心脏导管实验室的主任，在那里他目前是医学副教授。Chou博士在卡内基梅隆大学（Carnegie Mellon University）获得物理与电气工程学士学位，并在凯斯西储大学（Case Western Reserve University）获得医学博士学位。
- Tony M. Chou has served as a member of our board of directors since March 2007. Dr. Chou has been a general partner at The Vertical Group, a healthcare-focused venture capital firm, since August 2006. After joining The Vertical Group, Dr. Chou co-founded our company in 2007 and served as Chief Executive Officer until November 2010. Prior to that, Dr. Chou had general management and business development responsibilities in the Abbott Vascular Division of Abbott Laboratories and last served as Division Vice President and General Manager of vascular closure, managing the FDA approval and global launch of the Perclose and Starclose products. Dr. Chou was previously the Director of the Adult Cardiac Catheterization Laboratory at the University of California, San Francisco, where he is currently Associate Professor of Medicine. Dr. Chou received a B.S. in physics and electrical engineering from Carnegie Mellon University and an M.D. from Case Western Reserve University.
- Robert E. Mittendorff
-
RobertE.Mittendorff自2017年7月以来一直担任我们的董事会成员。Mittendorff博士从2012年2月开始一直担任Norwest Venture Partners的合伙人。Mittendorff博士曾任HansenMedical，Inc.营销和业务发展副总裁。Mittendorff博士目前在几家私人公司的董事会任职，也是董事会认证的急诊医师。Mittendorff博士在约翰霍普金斯大学（Johns Hopkins University）获得生物医学工程学士学位，在哈佛医学院（Harvard Medical School）获得医学博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Robert E. Mittendorff has served on our board of directors since July 2017. Dr. Mittendorff has been a partner at Norwest Venture Partners since February 2012. Dr. Mittendorff was previously the VP of Marketing and Business Development at Hansen Medical, Inc. Dr. Mittendorff currently serves on the board of directors of several private companies and is also a board certified emergency physician. Dr. Mittendorff received a B.S. in biomedical engineering from Johns Hopkins University, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School. - RobertE.Mittendorff自2017年7月以来一直担任我们的董事会成员。Mittendorff博士从2012年2月开始一直担任Norwest Venture Partners的合伙人。Mittendorff博士曾任HansenMedical，Inc.营销和业务发展副总裁。Mittendorff博士目前在几家私人公司的董事会任职，也是董事会认证的急诊医师。Mittendorff博士在约翰霍普金斯大学（Johns Hopkins University）获得生物医学工程学士学位，在哈佛医学院（Harvard Medical School）获得医学博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Robert E. Mittendorff has served on our board of directors since July 2017. Dr. Mittendorff has been a partner at Norwest Venture Partners since February 2012. Dr. Mittendorff was previously the VP of Marketing and Business Development at Hansen Medical, Inc. Dr. Mittendorff currently serves on the board of directors of several private companies and is also a board certified emergency physician. Dr. Mittendorff received a B.S. in biomedical engineering from Johns Hopkins University, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.
- Amr Kronfol
-
Amr Kronfol自2019年3月以来一直担任我们的董事会成员。Kronfol先生自2009年起受聘于华平（Warburg Pincus），自2018年起担任董事总经理，专注于梦百合，技术和消费/零售行业的投资活动。此前，他曾在美林（Merrill Lynch）和Tigris Consulting担任固定收益部门的Vice President。Kronfol先生任职于多家私人医疗和技术公司的董事会。Kronfol先生在普林斯顿大学（Princeton University）获得计算机科学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得工商管理硕士学位。
Amr Kronfol has served as a member of the Board since the closing of the Merger Transaction and previously served on Legacy SOC Telemed’s board of directors since June 2015. Mr. Kronfol joined Warburg Pincus, a private equity firm, in July 2009 and has been a Managing Director since 2018 focusing on investment activities at the intersection of healthcare and technology. Mr. Kronfol has served on numerous boards, including Silk Road Medical, AmRest, Modernizing Medicine, Qualifacts, WebPT and Helix. Mr. Kronfol holds an A.B. in computer science from Princeton University and an M.B.A. from The Wharton School at the University of Pennsylvania. - Amr Kronfol自2019年3月以来一直担任我们的董事会成员。Kronfol先生自2009年起受聘于华平（Warburg Pincus），自2018年起担任董事总经理，专注于梦百合，技术和消费/零售行业的投资活动。此前，他曾在美林（Merrill Lynch）和Tigris Consulting担任固定收益部门的Vice President。Kronfol先生任职于多家私人医疗和技术公司的董事会。Kronfol先生在普林斯顿大学（Princeton University）获得计算机科学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得工商管理硕士学位。
- Amr Kronfol has served as a member of the Board since the closing of the Merger Transaction and previously served on Legacy SOC Telemed’s board of directors since June 2015. Mr. Kronfol joined Warburg Pincus, a private equity firm, in July 2009 and has been a Managing Director since 2018 focusing on investment activities at the intersection of healthcare and technology. Mr. Kronfol has served on numerous boards, including Silk Road Medical, AmRest, Modernizing Medicine, Qualifacts, WebPT and Helix. Mr. Kronfol holds an A.B. in computer science from Princeton University and an M.B.A. from The Wharton School at the University of Pennsylvania.
- Elizabeth H. Weatherman
-
Elizabeth H. Weatherman，2006年7月至今，担任本公司的董事。本公司与某些本公司股票持有人之间订立了证券持有人协议，她因而被任命为董事。关于该证券持有人协议的更多信息，请参考以下关于Board Structure and Composition的讨论。她目前是Warburg Pincus & Co.的普通合伙人，以及Warburg Pincus LLC的董事总经理、执行管理小组成员。她于1988年加入Warburg Pincus，目前负责其美国医疗保健行业的投资业务。Warburg Pincus LLC 和 Warburg Pincus & Co.是Warburg Pincus的旗下公司，在此份委托书中统称为Warburg Pincus，它是本公司的大股东，截止2014年5月1日，拥有本公司近22.1%的普通流通股。她现在是一些私营公司的董事。在过去的5年，她担任上市公司 ev3，及其它一些私营公司的董事。另外，5年之前，她曾在医疗器械行业的一些上市公司担任董事。她在Stanford Graduate School of Business获得工商管理硕士学位，在Mount Holyoke College获得学士学位。
Elizabeth H. Weatherman,has served on Board of Directors since February 2022. She has been a Special Limited Partner of Warburg Pincus since January 2016. Ms. Weatherman joined Warburg Pincus in 1988 and led the firm's Healthcare Group from 2008 to 2015. She was also previously a Managing Director and a member of the firm's Executive Management Group. Ms. Weatherman serves as a director of Nevro Corp. and Stanford Health Care. She serves as a trustee of Stanford University and as a trustee and chair of the Investment Committee of Mount Holyoke College. Ms. Weatherman received a BA in English from Mount Holyoke College and holds an MBA from the Stanford Graduate School of Business. - Elizabeth H. Weatherman，2006年7月至今，担任本公司的董事。本公司与某些本公司股票持有人之间订立了证券持有人协议，她因而被任命为董事。关于该证券持有人协议的更多信息，请参考以下关于Board Structure and Composition的讨论。她目前是Warburg Pincus & Co.的普通合伙人，以及Warburg Pincus LLC的董事总经理、执行管理小组成员。她于1988年加入Warburg Pincus，目前负责其美国医疗保健行业的投资业务。Warburg Pincus LLC 和 Warburg Pincus & Co.是Warburg Pincus的旗下公司，在此份委托书中统称为Warburg Pincus，它是本公司的大股东，截止2014年5月1日，拥有本公司近22.1%的普通流通股。她现在是一些私营公司的董事。在过去的5年，她担任上市公司 ev3，及其它一些私营公司的董事。另外，5年之前，她曾在医疗器械行业的一些上市公司担任董事。她在Stanford Graduate School of Business获得工商管理硕士学位，在Mount Holyoke College获得学士学位。
- Elizabeth H. Weatherman,has served on Board of Directors since February 2022. She has been a Special Limited Partner of Warburg Pincus since January 2016. Ms. Weatherman joined Warburg Pincus in 1988 and led the firm's Healthcare Group from 2008 to 2015. She was also previously a Managing Director and a member of the firm's Executive Management Group. Ms. Weatherman serves as a director of Nevro Corp. and Stanford Health Care. She serves as a trustee of Stanford University and as a trustee and chair of the Investment Committee of Mount Holyoke College. Ms. Weatherman received a BA in English from Mount Holyoke College and holds an MBA from the Stanford Graduate School of Business.
- Donald J. Zurbay
-
Donald J. Zurbay自2018年3月起担任Silk Road Medical, Inc.的董事。Zurbay先生自2018年6月起担任Patterson公司（上市的全球医疗设备公司）的首席财务官。从2004年3月到2017年2月，Zurbay先生在St. Jude Medical, Inc.担任各种领导职务，他最近担任副总裁兼首席财务官（从2012年8月到2017年1月）。Zurbay先生曾在普华永道会计师事务所（PricewaterhouseCoopers）担任担保和商业咨询服务高级经理。加入PricewaterhouseCoopers之前，他是The Valspar Corporation的会计总经理。加入The Valspar Corporation之前，Zurbay先生是Deloitte & Touche的审计师。他是美国注册会计师协会（American Institute of Certified Accountants）和明尼苏达注册会计师协会（the Minnesota Society of Certified Public Accountants）的成员。他获得了明尼苏达大学（the University of Minnesota）的商业学士学位（侧重于会计）。
Donald J. Zurbay,became Patterson Companies, Inc. President and Chief Executive Officer in October 2022. Mr. Zurbay previously served as Patterson Companies, Inc. Chief Financial Officer from June 2018 through October 2022. Prior to that, Mr. Zurbay served as Vice President and Chief Financial Officer at global medical device manufacturer St. Jude Medical, Inc. from August 2012 through the January 2017 acquisition of St. Jude Medical by Abbott Laboratories. At St. Jude Medical, Mr. Zurbay was responsible for all accounting, financial and business development activities. He joined St. Jude Medical in 2003 and held various leadership positions, including Director of Finance and Vice President and Corporate Controller. Prior to joining St. Jude Medical, Mr. Zurbay worked at PricewaterhouseCoopers for five years as an Assurance and Business Advisory Services Senior Manager. Before joining PricewaterhouseCoopers, he was a General Accounting Manager at The Valspar Corporation. Mr. Zurbay started his career at Deloitte & Touche as an auditor in 1989. - Donald J. Zurbay自2018年3月起担任Silk Road Medical, Inc.的董事。Zurbay先生自2018年6月起担任Patterson公司（上市的全球医疗设备公司）的首席财务官。从2004年3月到2017年2月，Zurbay先生在St. Jude Medical, Inc.担任各种领导职务，他最近担任副总裁兼首席财务官（从2012年8月到2017年1月）。Zurbay先生曾在普华永道会计师事务所（PricewaterhouseCoopers）担任担保和商业咨询服务高级经理。加入PricewaterhouseCoopers之前，他是The Valspar Corporation的会计总经理。加入The Valspar Corporation之前，Zurbay先生是Deloitte & Touche的审计师。他是美国注册会计师协会（American Institute of Certified Accountants）和明尼苏达注册会计师协会（the Minnesota Society of Certified Public Accountants）的成员。他获得了明尼苏达大学（the University of Minnesota）的商业学士学位（侧重于会计）。
- Donald J. Zurbay,became Patterson Companies, Inc. President and Chief Executive Officer in October 2022. Mr. Zurbay previously served as Patterson Companies, Inc. Chief Financial Officer from June 2018 through October 2022. Prior to that, Mr. Zurbay served as Vice President and Chief Financial Officer at global medical device manufacturer St. Jude Medical, Inc. from August 2012 through the January 2017 acquisition of St. Jude Medical by Abbott Laboratories. At St. Jude Medical, Mr. Zurbay was responsible for all accounting, financial and business development activities. He joined St. Jude Medical in 2003 and held various leadership positions, including Director of Finance and Vice President and Corporate Controller. Prior to joining St. Jude Medical, Mr. Zurbay worked at PricewaterhouseCoopers for five years as an Assurance and Business Advisory Services Senior Manager. Before joining PricewaterhouseCoopers, he was a General Accounting Manager at The Valspar Corporation. Mr. Zurbay started his career at Deloitte & Touche as an auditor in 1989.
- Jack W. Lasersohn
-
Jack W. Lasersohn，他担任我们董事会董事（自2005年7月以来）和首席董事（自2013年8月以来）。自1989年以来，他担任Vertical Group（一个私人风险投资公司从事于医疗技术和生物技术领域）的普通合伙人或经理。此前，他担任副总裁。然后他担任F. Eberstadt & Co., Inc.（一家投资银行，The Vertical Group的前身公司）的风险投资部门的董事。自1995年以来，他在Alexza Pharmaceuticals, Inc.（一个上市的制药公司）的董事会任职。在那里，他担任其薪酬委员会成员以及提名和治理委员会的主席。自1982年起，他在公共和私人医疗或生物技术公司工作40余年，并且在美国风险投资协会（National Venture Capital Association ）的董事会的执行委员会任职。在总统办公司的任命下他在美国食品和药物管理局（the U.S. Food and Drug Administration）的创业家住宅项目的战略团队任职。他是由CMS任命的咨询委员会专家组（MEDCAC Panel）的小组成员。他获得塔夫斯大学（Tufts University）的物理学学士学位、弗莱彻法律与外交学院（The Fletcher School of Law and Diplomacy）的硕士学位和耶鲁法学院（ Yale Law School）的博士学位。
Jack W. Lasersohn has served as a member of our Board since April 2007. Since 1988 Mr. Lasersohn has been a general partner, or a principal of the general partner, of The Vertical Group, L.P., a private venture capital firm that is focused on the fields of medical technology and biotechnology. The Vertical Group was a co-founder of our company. Prior to joining The Vertical Group’s predecessor, F. Eberstadt, in 1981 Mr. Lasersohn was a corporate attorney with Cravath, Swaine & Moore LLP. Mr. Lasersohn served on the board of directors of Masimo Corporation, a publicly traded global medical technology company, from January 1995 to 2017 and has served on the board of directors of OncoMed Pharmaceuticals, Inc., a publicly traded clinical development-stage biopharmaceutical company, since July 2005. He also serves on the boards of a number of private medical device and biotechnology companies. Mr. Lasersohn is the past Chairman of the Medical Industry Group of the National Venture Capital Association, or NVCA, and previously served on the Executive Committee of the board of directors of the NVCA. Mr. Lasersohn has also served, by appointment, on various committees advising the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services. He holds a B.S. in physics from Tufts University, an M.A. from The Fletcher School of Law and Diplomacy, and a J.D. from Yale Law School. - Jack W. Lasersohn，他担任我们董事会董事（自2005年7月以来）和首席董事（自2013年8月以来）。自1989年以来，他担任Vertical Group（一个私人风险投资公司从事于医疗技术和生物技术领域）的普通合伙人或经理。此前，他担任副总裁。然后他担任F. Eberstadt & Co., Inc.（一家投资银行，The Vertical Group的前身公司）的风险投资部门的董事。自1995年以来，他在Alexza Pharmaceuticals, Inc.（一个上市的制药公司）的董事会任职。在那里，他担任其薪酬委员会成员以及提名和治理委员会的主席。自1982年起，他在公共和私人医疗或生物技术公司工作40余年，并且在美国风险投资协会（National Venture Capital Association ）的董事会的执行委员会任职。在总统办公司的任命下他在美国食品和药物管理局（the U.S. Food and Drug Administration）的创业家住宅项目的战略团队任职。他是由CMS任命的咨询委员会专家组（MEDCAC Panel）的小组成员。他获得塔夫斯大学（Tufts University）的物理学学士学位、弗莱彻法律与外交学院（The Fletcher School of Law and Diplomacy）的硕士学位和耶鲁法学院（ Yale Law School）的博士学位。
- Jack W. Lasersohn has served as a member of our Board since April 2007. Since 1988 Mr. Lasersohn has been a general partner, or a principal of the general partner, of The Vertical Group, L.P., a private venture capital firm that is focused on the fields of medical technology and biotechnology. The Vertical Group was a co-founder of our company. Prior to joining The Vertical Group’s predecessor, F. Eberstadt, in 1981 Mr. Lasersohn was a corporate attorney with Cravath, Swaine & Moore LLP. Mr. Lasersohn served on the board of directors of Masimo Corporation, a publicly traded global medical technology company, from January 1995 to 2017 and has served on the board of directors of OncoMed Pharmaceuticals, Inc., a publicly traded clinical development-stage biopharmaceutical company, since July 2005. He also serves on the boards of a number of private medical device and biotechnology companies. Mr. Lasersohn is the past Chairman of the Medical Industry Group of the National Venture Capital Association, or NVCA, and previously served on the Executive Committee of the board of directors of the NVCA. Mr. Lasersohn has also served, by appointment, on various committees advising the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services. He holds a B.S. in physics from Tufts University, an M.A. from The Fletcher School of Law and Diplomacy, and a J.D. from Yale Law School.
高管简历
中英对照 | 中文 | 英文- Erica J. Rogers
EricaJ.Rogers自2020年9月以来一直担任我们的董事会成员。Rogers女士自2012年10月起担任Silk Road Medical Inc.（一家医疗设备制造商）的总裁兼首席执行官和董事会成员。Rogers之前从2010年6月到2012年10月担任Medicines360（一家非盈利制药公司，为女性开发药物和设备）首席运营官。Rogers女士于2008年12月至2010年3月担任量子点技术公司NanoSys，Inc.的执行Vice President。在此之前，Rogers女士创立并担任Allux Medical（一家医疗设备公司）的首席执行官，并共同创立VisioGen（一家眼科医疗设备公司，于2009年被Abbott Medical Optics收购）。她此前曾任职Target Therapeutics Inc.（医疗设备制造商）的神经血管营销，以及Boston Scientific公司（医疗设备制造商）的外周血管销售和销售培训。Rogers女士目前在Sight Sciences，Inc.（一家医疗设备公司）的董事会任职。Rogers女士在圣地亚哥州立大学（San Diego State University）获得动物学学士学位。
Erica J. Rogers has served as a member of our board of directors since September 2020. Ms. Rogers has served as President and Chief Executive Officer and a member of the board of directors of Silk Road Medical Inc., a medical equipment manufacturer, since October 2012. Ms. Rogers previously served as Chief Operating Officer of Medicines360 a non-profit pharmaceutical company developing drugs and devices for women from June 2010 to October 2012. Ms. Rogers was an Executive Vice President at Nanosys, Inc., a quantum dot technology company, from December 2008 to March 2010. Prior to that, Ms. Rogers founded and was Chief Executive Officer of Allux Medical, a medical device company, and co-founded Visiogen, an ophthalmic medical device company which was acquired by Abbott Medical Optics in 2009. She worked previously in neurovascular marketing at Target Therapeutics Inc., a medical equipment manufacturer, and peripheral vascular sales and sales training at Boston Scientific, a medical device manufacturer. Ms. Rogers currently serves on the board of directors of Sight Sciences, Inc., a medical device company. Ms. Rogers received a B.S. in zoology from San Diego State University.- EricaJ.Rogers自2020年9月以来一直担任我们的董事会成员。Rogers女士自2012年10月起担任Silk Road Medical Inc.（一家医疗设备制造商）的总裁兼首席执行官和董事会成员。Rogers之前从2010年6月到2012年10月担任Medicines360（一家非盈利制药公司，为女性开发药物和设备）首席运营官。Rogers女士于2008年12月至2010年3月担任量子点技术公司NanoSys，Inc.的执行Vice President。在此之前，Rogers女士创立并担任Allux Medical（一家医疗设备公司）的首席执行官，并共同创立VisioGen（一家眼科医疗设备公司，于2009年被Abbott Medical Optics收购）。她此前曾任职Target Therapeutics Inc.（医疗设备制造商）的神经血管营销，以及Boston Scientific公司（医疗设备制造商）的外周血管销售和销售培训。Rogers女士目前在Sight Sciences，Inc.（一家医疗设备公司）的董事会任职。Rogers女士在圣地亚哥州立大学（San Diego State University）获得动物学学士学位。
- Erica J. Rogers has served as a member of our board of directors since September 2020. Ms. Rogers has served as President and Chief Executive Officer and a member of the board of directors of Silk Road Medical Inc., a medical equipment manufacturer, since October 2012. Ms. Rogers previously served as Chief Operating Officer of Medicines360 a non-profit pharmaceutical company developing drugs and devices for women from June 2010 to October 2012. Ms. Rogers was an Executive Vice President at Nanosys, Inc., a quantum dot technology company, from December 2008 to March 2010. Prior to that, Ms. Rogers founded and was Chief Executive Officer of Allux Medical, a medical device company, and co-founded Visiogen, an ophthalmic medical device company which was acquired by Abbott Medical Optics in 2009. She worked previously in neurovascular marketing at Target Therapeutics Inc., a medical equipment manufacturer, and peripheral vascular sales and sales training at Boston Scientific, a medical device manufacturer. Ms. Rogers currently serves on the board of directors of Sight Sciences, Inc., a medical device company. Ms. Rogers received a B.S. in zoology from San Diego State University.
- Lucas W. Buchanan
LucasW.Buchanan自2016年7月起担任我们的首席财务官，自2009年8月起担任多个职位，包括执行Vice President，商业化和企业发展以及Vice President，营销和业务发展。从2013年5月到2014年5月，Buchanan先生担任Impax Laboratories的战略与企业发展部的高级总监。Buchanan从2009年到2011年担任Vertical Group（一家风险投资公司和公司创始人）早期团队成员。他此前曾任职Medtronic公司、Ernst&Young Corporate Finance LLC。Buchanan先生在杜克大学（Duke University）获得经济学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得医疗保健管理工商管理硕士学位。
Lucas W. Buchanan has served as our Chief Financial Officer since July 2016 and since August 2009 has held multiple roles including Executive Vice President, Commercialization and Corporate Development and Vice President, Marketing and Business Development. From May 2013 to May 2014 Mr. Buchanan was a Senior Director of Strategy and Corporate Development at Impax Laboratories. From 2009 to 2011 Mr. Buchanan was part of our early team while employed at The Vertical Group, a venture capital firm and the founder of our company. He previously worked at Medtronic and at Ernst & Young Corporate Finance LLC. Mr. Buchanan received a B.A. in economics from Duke University and an M.B.A. in health care management from The Wharton School at the University of Pennsylvania.- LucasW.Buchanan自2016年7月起担任我们的首席财务官，自2009年8月起担任多个职位，包括执行Vice President，商业化和企业发展以及Vice President，营销和业务发展。从2013年5月到2014年5月，Buchanan先生担任Impax Laboratories的战略与企业发展部的高级总监。Buchanan从2009年到2011年担任Vertical Group（一家风险投资公司和公司创始人）早期团队成员。他此前曾任职Medtronic公司、Ernst&Young Corporate Finance LLC。Buchanan先生在杜克大学（Duke University）获得经济学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得医疗保健管理工商管理硕士学位。
- Lucas W. Buchanan has served as our Chief Financial Officer since July 2016 and since August 2009 has held multiple roles including Executive Vice President, Commercialization and Corporate Development and Vice President, Marketing and Business Development. From May 2013 to May 2014 Mr. Buchanan was a Senior Director of Strategy and Corporate Development at Impax Laboratories. From 2009 to 2011 Mr. Buchanan was part of our early team while employed at The Vertical Group, a venture capital firm and the founder of our company. He previously worked at Medtronic and at Ernst & Young Corporate Finance LLC. Mr. Buchanan received a B.A. in economics from Duke University and an M.B.A. in health care management from The Wharton School at the University of Pennsylvania.
- Andrew S. Davis
AndrewS.Davis于2015年5月加入我们，担任全球销售与市场营销执行Vice President。2014年9月至2015年5月，戴维斯先生是美国和加拿大销售与市场营销的Vice President，隶属于Acelity高级伤口治疗小组。Davis先生曾于1999年至2014年9月在美敦力公司担任多个领导职位，在那里他最近担任CoreValve导管基础疗法的美国销售Vice President，并在此之前担任美国血管内销售Vice President。在Medtronic之前，Davis先生在Boston Scientific从事销售工作。Davis先生在佛罗里达州立大学（Florida State University）获得政治学学士学位。
Andrew S. Davis joined us in May 2015 as our Executive Vice President of Global Sales and Marketing. From September 2014 to May 2015 Mr. Davis was Vice President of Sales and Marketing for U.S. and Canada in the Advanced Wound Therapy Group of Acelity. Mr. Davis previously held various leadership positions at Medtronic from 1999 until September 2014 where he most recently served as U.S. Vice President of Sales for CoreValve catheter-based therapies and prior to that U.S. Vice President of Sales for Endovascular. Prior to Medtronic, Mr. Davis worked in sales at Boston Scientific. Mr. Davis received a B.S. in political science from Florida State University.- AndrewS.Davis于2015年5月加入我们，担任全球销售与市场营销执行Vice President。2014年9月至2015年5月，戴维斯先生是美国和加拿大销售与市场营销的Vice President，隶属于Acelity高级伤口治疗小组。Davis先生曾于1999年至2014年9月在美敦力公司担任多个领导职位，在那里他最近担任CoreValve导管基础疗法的美国销售Vice President，并在此之前担任美国血管内销售Vice President。在Medtronic之前，Davis先生在Boston Scientific从事销售工作。Davis先生在佛罗里达州立大学（Florida State University）获得政治学学士学位。
- Andrew S. Davis joined us in May 2015 as our Executive Vice President of Global Sales and Marketing. From September 2014 to May 2015 Mr. Davis was Vice President of Sales and Marketing for U.S. and Canada in the Advanced Wound Therapy Group of Acelity. Mr. Davis previously held various leadership positions at Medtronic from 1999 until September 2014 where he most recently served as U.S. Vice President of Sales for CoreValve catheter-based therapies and prior to that U.S. Vice President of Sales for Endovascular. Prior to Medtronic, Mr. Davis worked in sales at Boston Scientific. Mr. Davis received a B.S. in political science from Florida State University.
- Richard M. Ruedy
RichardM.Ruedy于2011年加入我们，是临床和法规事务以及质量保证的执行Vice President。Ruedy先生曾于2009年至2010年担任Nevro Corporation监管、临床和质量Vice President。在加入Nevro之前，Ruedy先生曾于2007年4月至2009年5月担任Cardica Inc.监管、临床和质量事务Vice President。Ruedy先生此前还曾担任雅培血管（Abbott Vascular）的监管事务总监，共同创立了被Covidien收购的ACTA Vascular，并曾在Edwards LifeScienses，美敦力，Becton Dickinson收购的TriPath Imaging和ArthroCare收购的Parallax Medical担任职责递增的职位。Ruedy先生在巴克内尔大学（Bucknell University）获得英语与国际关系学士学位。
Richard M. Ruedy joined us in 2011 and is the Executive Vice President of Clinical and Regulatory Affairs, and Quality Assurance. Mr. Ruedy was previously Vice President of Regulatory, Clinical and Quality for Nevro Corporation from 2009 to 2010 Prior to Nevro, Mr. Ruedy served as Vice President of Regulatory Clinical and Quality affairs of Cardica Inc. from April 2007 to May 2009. Mr. Ruedy also previously served as Director of Regulatory Affairs at Abbott Vascular, co-founded Acta Vascular acquired by Covidien and previously held positions of increasing responsibility at Edwards Lifescienses, Medtronic, TriPath Imaging acquired by Becton Dickinson, and Parallax Medical acquired by Arthrocare. Mr. Ruedy received a B.A. in English and international relations from Bucknell University.- RichardM.Ruedy于2011年加入我们，是临床和法规事务以及质量保证的执行Vice President。Ruedy先生曾于2009年至2010年担任Nevro Corporation监管、临床和质量Vice President。在加入Nevro之前，Ruedy先生曾于2007年4月至2009年5月担任Cardica Inc.监管、临床和质量事务Vice President。Ruedy先生此前还曾担任雅培血管（Abbott Vascular）的监管事务总监，共同创立了被Covidien收购的ACTA Vascular，并曾在Edwards LifeScienses，美敦力，Becton Dickinson收购的TriPath Imaging和ArthroCare收购的Parallax Medical担任职责递增的职位。Ruedy先生在巴克内尔大学（Bucknell University）获得英语与国际关系学士学位。
- Richard M. Ruedy joined us in 2011 and is the Executive Vice President of Clinical and Regulatory Affairs, and Quality Assurance. Mr. Ruedy was previously Vice President of Regulatory, Clinical and Quality for Nevro Corporation from 2009 to 2010 Prior to Nevro, Mr. Ruedy served as Vice President of Regulatory Clinical and Quality affairs of Cardica Inc. from April 2007 to May 2009. Mr. Ruedy also previously served as Director of Regulatory Affairs at Abbott Vascular, co-founded Acta Vascular acquired by Covidien and previously held positions of increasing responsibility at Edwards Lifescienses, Medtronic, TriPath Imaging acquired by Becton Dickinson, and Parallax Medical acquired by Arthrocare. Mr. Ruedy received a B.A. in English and international relations from Bucknell University.